JPH09194356A - Internal liquid preparation compounded with iron compound - Google Patents
Internal liquid preparation compounded with iron compoundInfo
- Publication number
- JPH09194356A JPH09194356A JP8006195A JP619596A JPH09194356A JP H09194356 A JPH09194356 A JP H09194356A JP 8006195 A JP8006195 A JP 8006195A JP 619596 A JP619596 A JP 619596A JP H09194356 A JPH09194356 A JP H09194356A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- iron
- organic
- component
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002506 iron compounds Chemical class 0.000 title claims abstract description 23
- 239000007788 liquid Substances 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 45
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229910052742 iron Inorganic materials 0.000 claims abstract description 22
- 150000007524 organic acids Chemical class 0.000 claims abstract description 13
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 12
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000001630 malic acid Substances 0.000 claims abstract description 12
- 235000011090 malic acid Nutrition 0.000 claims abstract description 12
- 235000015165 citric acid Nutrition 0.000 claims abstract description 10
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000011575 calcium Substances 0.000 claims abstract description 8
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000005985 organic acids Nutrition 0.000 claims abstract description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000013329 compounding Methods 0.000 claims abstract description 5
- 239000011975 tartaric acid Substances 0.000 claims abstract description 5
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 5
- 239000004310 lactic acid Substances 0.000 claims abstract description 4
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 3
- 239000001530 fumaric acid Substances 0.000 claims abstract description 3
- 235000011087 fumaric acid Nutrition 0.000 claims abstract description 3
- 239000001384 succinic acid Substances 0.000 claims abstract description 3
- 235000011044 succinic acid Nutrition 0.000 claims abstract description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 3
- PLKYGPRDCKGEJH-UHFFFAOYSA-N azane;2-hydroxypropane-1,2,3-tricarboxylic acid;iron Chemical compound N.[Fe].OC(=O)CC(O)(C(O)=O)CC(O)=O PLKYGPRDCKGEJH-UHFFFAOYSA-N 0.000 claims description 22
- 239000004227 calcium gluconate Substances 0.000 claims description 10
- 229960004494 calcium gluconate Drugs 0.000 claims description 10
- 235000013927 calcium gluconate Nutrition 0.000 claims description 10
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 10
- 229960005069 calcium Drugs 0.000 claims description 5
- 229940043430 calcium compound Drugs 0.000 claims description 5
- 150000001674 calcium compounds Chemical class 0.000 claims description 5
- 229940100688 oral solution Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 235000019640 taste Nutrition 0.000 abstract description 8
- 208000025371 Taste disease Diseases 0.000 abstract description 4
- 235000019656 metallic taste Nutrition 0.000 abstract description 4
- 208000007502 anemia Diseases 0.000 abstract description 3
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 abstract description 2
- 239000004313 iron ammonium citrate Substances 0.000 abstract description 2
- 235000000011 iron ammonium citrate Nutrition 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 1
- ILJIJWPWFKABMW-VAQXQGSJSA-L calcium;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoate Chemical compound [Ca+2].O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C([O-])=O.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C([O-])=O ILJIJWPWFKABMW-VAQXQGSJSA-L 0.000 abstract 1
- 229960004642 ferric ammonium citrate Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000008213 purified water Substances 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 19
- 150000003839 salts Chemical group 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229960001948 caffeine Drugs 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 5
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 description 5
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 5
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 5
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 5
- 229940023137 pyridoxine hydrochloride 20 mg Drugs 0.000 description 5
- 235000019265 sodium DL-malate Nutrition 0.000 description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 5
- 239000001394 sodium malate Substances 0.000 description 5
- 229950001574 riboflavin phosphate Drugs 0.000 description 4
- 239000004299 sodium benzoate Substances 0.000 description 4
- 235000010234 sodium benzoate Nutrition 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000009538 yokuinin Substances 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 244000228451 Stevia rebaudiana Species 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008369 fruit flavor Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000013532 brandy Nutrition 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940109850 royal jelly Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 240000004731 Acer pseudoplatanus Species 0.000 description 1
- 235000002754 Acer pseudoplatanus Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000951471 Citrus junos Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 239000005749 Copper compound Substances 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 235000017048 Garcinia mangostana Nutrition 0.000 description 1
- 240000006053 Garcinia mangostana Species 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 241000282375 Herpestidae Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 229930182844 L-isoleucine Natural products 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 235000000556 Paullinia cupana Nutrition 0.000 description 1
- 240000003444 Paullinia cupana Species 0.000 description 1
- 235000006485 Platanus occidentalis Nutrition 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 241000340987 Ptychopetalum olacoides Species 0.000 description 1
- 235000005733 Raphanus sativus var niger Nutrition 0.000 description 1
- 244000155437 Raphanus sativus var. niger Species 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 229940114117 calcium gluconate 1000 mg Drugs 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 150000001880 copper compounds Chemical class 0.000 description 1
- HWDGVJUIHRPKFR-UHFFFAOYSA-I copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Cu+2].N1=C(C(CC([O-])=O)=C2C(C(C)C(C=C3C(=C(C=C)C(=C4)[N-]3)C)=N2)CCC([O-])=O)C(=C([O-])[O-])C(C)=C1C=C1C(CC)=C(C)C4=N1 HWDGVJUIHRPKFR-UHFFFAOYSA-I 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- -1 etc. can be used Chemical compound 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 235000020094 liqueur Nutrition 0.000 description 1
- 239000008374 liqueur flavor Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 229940033253 malic acid 600 mg Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 150000003112 potassium compounds Chemical class 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000013533 rum Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 150000003388 sodium compounds Chemical class 0.000 description 1
- 235000013758 sodium copper chlorophyllin Nutrition 0.000 description 1
- 229940079841 sodium copper chlorophyllin Drugs 0.000 description 1
- KXFFQVUPQCREHA-UHFFFAOYSA-K sodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KXFFQVUPQCREHA-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は鉄由来の金属味が軽減さ
れた鉄化合物配合内服液剤に関するものであり、医薬、
食品の分野に応用できるものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an iron compound-containing oral solution containing a reduced iron-derived metallic taste,
It can be applied to the field of food.
【0002】[0002]
【従来の技術】鉄は成人の体内に約3g含まれており、
主に血液中の赤血球のヘモグロビン、筋肉のミオグロビ
ン及び肝臓のフェリチンに含まれ、一部は全身の細胞に
広く分布している微量金属元素である。鉄の生理作用と
しては、次のものなどが挙げられる。ヘモグロビンの鉄
は酸素を運搬し、ミオグロビンの鉄は血中の酸素を細胞
に取り入れる。各細胞の鉄は、酸素の活性化に関係し、
栄養素の燃焼に役立っている。このように鉄は生体上必
要不可欠な金属であるが、その独特の味ゆえにあまり味
覚に作用されない錠剤を主とする固形剤が主に使われて
いる。2. Description of the Related Art Iron contains about 3 g in an adult body,
It is mainly contained in hemoglobin of red blood cells in blood, myoglobin of muscle and ferritin of liver, and part of it is a trace metal element widely distributed in cells throughout the body. The physiological actions of iron include the following. The iron in hemoglobin carries oxygen, and the iron in myoglobin takes oxygen in the blood into cells. Iron in each cell is involved in the activation of oxygen,
Helps burn nutrients. As described above, iron is an indispensable metal in the living body, but due to its unique taste, solid agents mainly composed of tablets that are not so much affected by taste are mainly used.
【0003】[0003]
【発明が解決しようとする課題】従来より鉄分を補給す
るには、鉄由来の独特な味のため水溶液で経口的に補給
するのには向いていなかった。本発明の目的は、鉄由来
の不快な味をマスキングし、貧血の予防などに対して極
めて有効な鉄分補給内服液剤を提供することである。[Problems to be Solved by the Invention] Conventionally, iron has not been suitable for oral supplementation with an aqueous solution because of its unique taste derived from iron. An object of the present invention is to provide an iron supplement oral liquid which masks unpleasant taste derived from iron and is extremely effective for prevention of anemia and the like.
【0004】[0004]
【課題を解決するための手段】本発明らは鋭意研究を進
めた結果、有機鉄化合物及び、1種または2種以上の有
機酸を配合し、pHを2.5〜5.0、好ましくはpH
3.0〜4.5に調整した鉄化合物配合内服液剤が課題
を解決できることを見いだし、本発明を完成した。本発
明において用いられる有機鉄化合物としては、クエン酸
鉄、クエン酸鉄アンモニウム、クエン酸鉄ナトリウム、
グルコン酸第一鉄、乳酸鉄などであり、中でもクエン酸
鉄アンモニウムが好ましい。有機鉄化合物の摂取量は、
有機鉄化合物中の鉄成分に換算して1日0.5〜18m
gである。As a result of intensive studies, the present inventors have added an organic iron compound and one or more organic acids, and have a pH of 2.5 to 5.0, preferably pH
The inventors have found that an iron compound-containing oral solution adjusted to 3.0 to 4.5 can solve the problems, and completed the present invention. Examples of the organic iron compound used in the present invention include iron citrate, ammonium iron citrate, sodium iron citrate,
Examples thereof include ferrous gluconate and iron lactate, with ammonium iron citrate being preferred. The intake of organic iron compounds is
0.5-18m / day converted to iron component in organic iron compound
g.
【0005】また、有機酸としてはクエン酸、リンゴ
酸、フマル酸、酒石酸、乳酸、コハク酸などを挙げるこ
とができる。上記有機酸は塩の形、例えばクエン酸ナト
リウムとして配合することもできる。それらの配合量
は、酸味が増すとマスキングが良好になるが、逆に酸味
が強すぎ服用しにくくなることから0.05〜2重量%
にすることが好ましい。また、有機鉄化合物中の鉄成分
1重量部に対して3〜300重量部配合することが好ま
しい。なお、有機酸を塩の形で配合する場合には、配合
量は有機酸に換算して決められる。Examples of the organic acid include citric acid, malic acid, fumaric acid, tartaric acid, lactic acid and succinic acid. The organic acids can also be formulated in salt form, for example sodium citrate. The amount of them is 0.05 to 2% by weight because the masking becomes better as the sourness increases, but conversely the sourness becomes too strong and it is difficult to take.
Is preferable. Further, it is preferable to add 3 to 300 parts by weight to 1 part by weight of the iron component in the organic iron compound. When the organic acid is blended in the form of a salt, the blending amount is determined in terms of the organic acid.
【0006】本発明においては、カルシウム化合物を配
合することが好ましく、その配合量は、0.001〜
1.0重量%であり、かつ有機鉄化合物中の鉄成分1重
量部あたりカルシウム成分1〜40重量部となる量であ
る。カルシウム成分量が0.001重量%を下回ると、
有機酸の配合量が少ない場合に鉄成分の味のマスキング
効果が悪くなり、また1.0重量%を上回ると、カルシ
ウムの金属味が生じるので好ましくない。なお、上記カ
ルシウム化合物を配合する場合には、有機酸の配合量は
0.01〜2.0重量%でよい。前記カルシウム化合物
としては、アスコルビン酸カルシウム、塩化カルシウ
ム、クエン酸カルシウム、グリセロリン酸カルシウム、
グルコン酸カルシウム、炭酸カルシウム、乳酸カルシウ
ム、パントテン酸カルシウム、リン酸水素カルシウムな
どを用いることができるが、中でもグルコン酸カルシウ
ムが好ましい。In the present invention, it is preferable to add a calcium compound, and the amount thereof is 0.001 to
The amount is 1.0% by weight and 1 to 40 parts by weight of calcium component per 1 part by weight of iron component in the organic iron compound. When the amount of calcium component is less than 0.001% by weight,
When the compounding amount of the organic acid is small, the taste masking effect of the iron component is deteriorated, and when it exceeds 1.0% by weight, a metallic taste of calcium occurs, which is not preferable. In addition, when the said calcium compound is mix | blended, the compounding quantity of an organic acid may be 0.01-2.0 weight%. As the calcium compound, calcium ascorbate, calcium chloride, calcium citrate, calcium glycerophosphate,
Although calcium gluconate, calcium carbonate, calcium lactate, calcium pantothenate, calcium hydrogen phosphate, etc. can be used, calcium gluconate is particularly preferable.
【0007】また、本発明の内服液剤にはその他の成分
として、ビタミン、ミネラル、アミノ酸及びその塩類、
生薬、甘味剤、保存剤、ローヤルゼリー、カフェイン、
γ−オリザノール、シベット、パンテノール、銅クロロ
フィリンナトリウム、コンドロイチン硫酸ナトリウム、
香料などを本発明の効果を損なわない範囲で配合するこ
とができる。ビタミンとしては、ビタミンB1またはそ
の誘導体またはその塩類、ビタミンB2またはその誘導
体またはその塩類、ビタミンB6またはその誘導体また
はその塩類、ビタミンCまたはその誘導体またはその塩
類、ビタミンEまたはその誘導体、ニコチン酸アミド、
葉酸、チオクト酸などを挙げることができる。In addition, the oral liquid preparation of the present invention also contains other components such as vitamins, minerals, amino acids and salts thereof,
Crude drug, sweetener, preservative, royal jelly, caffeine,
γ-oryzanol, civet, panthenol, sodium copper chlorophyllin, sodium chondroitin sulfate,
Fragrances and the like can be added within a range that does not impair the effects of the present invention. Examples of vitamins include vitamin B 1 or a derivative thereof or a salt thereof, vitamin B 2 or a derivative thereof or a salt thereof, vitamin B 6 or a derivative thereof or a salt thereof, vitamin C or a derivative thereof or a salt thereof, vitamin E or a derivative thereof, nicotine. Acid amide,
Examples thereof include folic acid and thioctic acid.
【0008】ミネラルとしては、亜鉛化合物、マグネシ
ウム化合物、銅化合物、ナトリウム化合物、カリウム化
合物などを挙げることができる。アミノ酸またはその塩
類としては、アミノエチルスルホン酸、L−ロイシン、
L−イソロイシン、L−リジン、L−メチオニン、L−
フェニルアラニン、L−スレオニン、L−トリプトファ
ン、L−バリン、L−ヒスチジン、L−アスパラギン
酸、L−アスパラギン酸マグネシウム、L−塩酸アルギ
ニンなどを挙げることができる。Examples of minerals include zinc compounds, magnesium compounds, copper compounds, sodium compounds and potassium compounds. Amino acids or salts thereof include aminoethyl sulfonic acid, L-leucine,
L-isoleucine, L-lysine, L-methionine, L-
Examples thereof include phenylalanine, L-threonine, L-tryptophan, L-valine, L-histidine, L-aspartic acid, magnesium L-aspartate, and L-arginine hydrochloride.
【0009】生薬としては、イカリソウ、エゾウコギ、
カイクジン、ガラナ、カンゾウ、クコシ、ゴオウ、ジオ
ウ、ハンピ、ブクリョウ、ニクジュヨウ、ニンジン、ヨ
クイニン、ムイラプアマなどを挙げることができる。甘
味剤としては、砂糖、果糖、ブドウ糖、液糖、ソルビト
ール、キシリトール、マルチトール、エリスリトール、
トレハロース、イノシトール、還元麦芽糖水飴、ステビ
ア抽出物、アスパルテームなどを挙げることができる。
保存剤としては、ニパメチ、ニパエチ、ニパプロ、ニパ
ブチなどのパラベン類、安息香酸またはその塩類、エデ
ト酸またはその塩類などを挙げることができる。Herbal medicines include Epimedium, Eleuthero,
Examples include kaijin, guarana, licorice, kokushi, sycamore, dio, hump, bukuro, daikon, carrot, yokinin, muirapuama and the like. As the sweetener, sugar, fructose, glucose, liquid sugar, sorbitol, xylitol, maltitol, erythritol,
Examples thereof include trehalose, inositol, reduced maltose syrup, stevia extract and aspartame.
Examples of the preservatives include parabens such as nipamethyi, nipaethi, nipapro and nipabuti, benzoic acid or salts thereof, edetic acid or salts thereof, and the like.
【0010】香料としては、オレンジ、グレープフルー
ツ、レモン、ライム、タンジェリン、ユズ、ウンシュウ
ミカン、ナツミカン、ブドウ、イチゴ、パイナップル、
バナナ、モモ、メロン、スイカ、プラム、チェリー、ペ
ア、アプリコット、カーラント、ウメ、マンゴ、マンゴ
スチン、グアバ、ラズベリー、ブルーベリーなどの果実
系フレーバー、緑茶、包種茶、紅茶、ココア、チョコレ
ート、コーヒー、アーモンド、メイプル、バニラ、ウィ
スキー、ブランデー、ラム、ワイン、リキュール、カク
テルなどのフレーバーが挙げられ、これらは単独あるい
は2種以上のミックスフレバーにして用いることができ
る。As the fragrance, orange, grapefruit, lemon, lime, tangerine, yuzu, citrus unshiu, natsumikan, grape, strawberry, pineapple,
Fruit flavors such as banana, peach, melon, watermelon, plum, cherry, pair, apricot, currant, plum, mango, mangosteen, guava, raspberry, blueberry, green tea, wrapped tea, tea, cocoa, chocolate, coffee, almond. , Maple, vanilla, whiskey, brandy, rum, wine, liqueur, cocktail, and the like, and these can be used alone or in combination of two or more kinds.
【0011】[0011]
【発明の効果】本発明により、鉄由来の不快な味が軽減
されかつカルシウムの金属味等もない非常に飲みやすい
鉄化合物配合内服液剤を提供することが可能となった。
従って、貧血などの予防に利用できる。INDUSTRIAL APPLICABILITY According to the present invention, it has become possible to provide a very easy-to-drink oral compound containing an iron compound in which the unpleasant taste derived from iron is reduced and the metallic taste of calcium is not present.
Therefore, it can be used for prevention of anemia and the like.
【0012】[0012]
【実施例】次に、実施例、比較例及び試験例を挙げて本
発明を更に詳細に説明する。 比較例1 クエン酸鉄アンモニウム 40mg 精製水 全量 200ml (製造方法)精製水200mlに処方量のクエン酸鉄ア
ンモニウムを溶解した(pH=6.1)。EXAMPLES Next, the present invention will be described in more detail with reference to Examples, Comparative Examples and Test Examples. Comparative Example 1 Ammonium iron citrate 40 mg Purified water Total amount 200 ml (Production method) A prescribed amount of ammonium iron citrate was dissolved in 200 ml of purified water (pH = 6.1).
【0013】比較例2 クエン酸鉄アンモニウム 240mg 精製水 全量 200ml (製造方法)比較例1と同様の方法で調製した(pH=
5.9)。Comparative Example 2 Ammonium iron citrate 240 mg Purified water Total amount 200 ml (Production method) Prepared in the same manner as in Comparative Example 1 (pH =
5.9).
【0014】比較例3 クエン酸鉄アンモニウム 40mg リンゴ酸 24mg 水酸化ナトリウム 適量 精製水 全量 200ml (製造方法)精製水200mlに処方量の上記成分を溶
解し、水酸化ナトリウムを用いpHを4.0に調節し
た。Comparative Example 3 Ammonium iron citrate 40 mg Malic acid 24 mg Sodium hydroxide Suitable amount Purified water Total amount 200 ml (Production method) The prescribed amounts of the above components were dissolved in purified water 200 ml, and the pH was adjusted to 4.0 with sodium hydroxide. I adjusted.
【0015】実施例1 クエン酸鉄アンモニウム 40mg クエン酸 140mg 精製水 全量 200ml (製造方法)精製水100mlに処方量の上記成分を溶
解し、さらに精製水を添加して全量200mlとした
(pH=3.0)。Example 1 Ammonium iron citrate 40 mg Citric acid 140 mg Purified water Total amount 200 ml (Production method) The prescribed amount of the above components were dissolved in purified water 100 ml, and purified water was added to make the total amount 200 ml (pH = 3). .0).
【0016】実施例2 クエン酸鉄アンモニウム 40mg クエン酸ナトリウム 80mg クエン酸 156mg 精製水 全量 200ml (製造方法)実施例1と同様の方法で調製した(pH=
4.0)。Example 2 Ammonium iron citrate 40 mg Sodium citrate 80 mg Citric acid 156 mg Purified water Total amount 200 ml (Production method) Prepared in the same manner as in Example 1 (pH =
4.0).
【0017】実施例3 クエン酸鉄アンモニウム 240mg クエン酸 256mg 精製水 全量 200ml (製造方法)実施例1と同様の方法で調製した(pH=
3.0)。Example 3 Ammonium iron citrate 240 mg Citric acid 256 mg Purified water Total amount 200 ml (Production method) Prepared in the same manner as in Example 1 (pH =
3.0).
【0018】実施例4 クエン酸鉄アンモニウム 240mg クエン酸ナトリウム 80mg クエン酸 124mg 精製水 全量 200ml (製造方法)実施例1と同様の方法で調製した(pH=
4.0)。Example 4 Ammonium iron citrate 240 mg Sodium citrate 80 mg Citric acid 124 mg Purified water Total amount 200 ml (Production method) Prepared in the same manner as in Example 1 (pH =
4.0).
【0019】実施例5 クエン酸鉄アンモニウム 240mg フマル酸一ナトリウム 80mg リンゴ酸ナトリウム 200mg 酒石酸 128mg 精製水 全量 200ml (製造方法)実施例1と同様の方法で調製した(pH=
4.0)。Example 5 Ammonium iron citrate 240 mg Monosodium fumarate 80 mg Sodium malate 200 mg Tartaric acid 128 mg Purified water Total amount 200 ml (Production method) Prepared by the same method as in Example 1 (pH =
4.0).
【0020】実施例6 クエン酸鉄アンモニウム 240mg リンゴ酸ナトリウム 80mg リンゴ酸 92mg 精製水 全量 200ml (製造方法)実施例1と同様の方法で調製した(pH=
4.0)。Example 6 Ammonium iron citrate 240 mg Sodium malate 80 mg Malic acid 92 mg Purified water Total amount 200 ml (Production method) Prepared in the same manner as in Example 1 (pH =
4.0).
【0021】実施例7 クエン酸鉄アンモニウム 240mg フマル酸一ナトリウム 80mg リンゴ酸ナトリウム 200mg 乳酸 204mg 精製水 全量 200ml (製造方法)実施例1と同様の方法で調製した(pH=
4.0)。Example 7 Ammonium iron citrate 240 mg Monosodium fumarate 80 mg Sodium malate 200 mg Lactic acid 204 mg Purified water Total amount 200 ml (Production method) Prepared in the same manner as in Example 1 (pH =
4.0).
【0022】実施例8 クエン酸鉄アンモニウム 40mg グルコン酸カルシウム 80mg リンゴ酸 24mg 精製水 全量 200ml (製造方法)実施例1と同様の方法で調製した(pH=
4.0)。Example 8 Ammonium iron citrate 40 mg Calcium gluconate 80 mg Malic acid 24 mg Purified water Total amount 200 ml (Production method) Prepared in the same manner as in Example 1 (pH =
4.0).
【0023】実施例9 クエン酸鉄アンモニウム 240mg グルコン酸カルシウム 480mg リンゴ酸 104mg 精製水 全量 200ml (製造方法)実施例1と同様の方法で調製した(pH=
4.0)。Example 9 Ammonium iron citrate 240 mg Calcium gluconate 480 mg Malic acid 104 mg Purified water Total amount 200 ml (Production method) Prepared in the same manner as in Example 1 (pH =
4.0).
【0024】実施例10 クエン酸鉄アンモニウム 240mg グルコン酸カルシウム 8000mg リンゴ酸 632mg 精製水 全量 200ml (製造方法)実施例1と同様の方法で調製した(pH=
4.0)。Example 10 Ammonium iron citrate 240 mg Calcium gluconate 8000 mg Malic acid 632 mg Purified water Total amount 200 ml (Production method) Prepared in the same manner as in Example 1 (pH =
4.0).
【0025】実施例11 グルコン酸カルシウム 800mg クエン酸鉄アンモニウム 72mg リン酸リボフラビンナトリウム 10mg 塩酸ピリドキシン 20mg 無水カフェイン 200mg アミノエチルスルホン酸 2000mg 砂糖 32000mg 安息香酸ナトリウム 60mg クエン酸 620mg トロピカルフルーツフレーバー 微量 精製水 全量 200ml (製造方法)精製水100mlに処方量の砂糖を撹拌溶
解し、その後他の成分を撹拌しながら順次添加し溶解を
確認した後、精製水を添加し全量200mlとする。そ
の時のpHは3.5であった。濾紙上にケイソウ土を薄
く均一に層とした濾過装置を使い本製剤を濾過した。そ
の後、濾液を滅菌装置を用いて95℃で60秒間滅菌し
た後、ビンに充填しキャップを施した。Example 11 Calcium gluconate 800 mg Ammonium iron citrate 72 mg Sodium riboflavin phosphate 10 mg Pyridoxine hydrochloride 20 mg Anhydrous caffeine 200 mg Aminoethyl sulfonic acid 2000 mg Sugar 32000 mg Sodium benzoate 60 mg Citrate 620 mg Tropical fruit flavor Total amount of purified water 200 ml ( Manufacturing method) A prescribed amount of sugar is stirred and dissolved in 100 ml of purified water, and then other components are sequentially added while stirring to confirm dissolution, and then purified water is added to make a total amount of 200 ml. The pH at that time was 3.5. This preparation was filtered using a filter device in which diatomaceous earth was thinly and uniformly layered on a filter paper. Then, the filtrate was sterilized by using a sterilizer at 95 ° C. for 60 seconds, then filled in a bottle and capped.
【0026】実施例12 グルコン酸カルシウム 800mg クエン酸鉄アンモニウム 80mg L−アスパラギン酸マグネシウム 400mg リン酸リボフラビンナトリウム 10mg 塩酸ピリドキシン 20mg 無水カフェイン 200mg アミノエチルスルホン酸 2000mg ヨクイニン 2400mg 還元麦芽糖水飴 10000mg 異性化糖 30000mg 安息香酸ナトリウム 60mg クエン酸ナトリウム 100mg クエン酸 600mg リンゴ酸 適量 チェリーブランデーフレーバー 微量 精製水 全量 200ml (製造方法)精製水100mlに処方量の砂糖を撹拌溶
解し、その後他の成分を撹拌しながら順次添加し溶解を
確認した後、精製水を添加し全量200mlとする。適
量成分であるリンゴ酸を添加しpHを3.5に調節後、
濾紙上にケイソウ土を薄く均一に層とした濾過装置を使
い本製剤を濾過した。その後、濾液を滅菌装置を用いて
95℃で60秒間滅菌した後、ビンに充填しキャップを
施した。Example 12 Calcium gluconate 800 mg Ammonium iron citrate 80 mg Magnesium L-aspartate 400 mg Riboflavin sodium phosphate 10 mg Pyridoxine hydrochloride 20 mg Anhydrous caffeine 200 mg Aminoethyl sulfonic acid 2000 mg Yokuinin 2400 mg Reduced maltose starch syrup 10000 mg Isomerized sugar 30,000 mg Benzoic acid Sodium 60mg Sodium citrate 100mg Citric acid 600mg Malic acid Appropriate amount Cherry brandy flavor Trace amount Purified water Total amount 200ml (Manufacturing method) Dissolve a prescribed amount of sugar with stirring in 100ml of purified water, and then add other ingredients sequentially with stirring to dissolve After checking, add purified water to make the total volume 200 ml. After adjusting the pH to 3.5 by adding an appropriate amount of malic acid,
This preparation was filtered using a filter device in which diatomaceous earth was thinly and uniformly layered on a filter paper. Then, the filtrate was sterilized by using a sterilizer at 95 ° C. for 60 seconds, then filled in a bottle and capped.
【0027】実施例13 グルコン酸カルシウム 800mg クエン酸鉄アンモニウム 80mg L−アスパラギン酸マグネシウム 400mg リン酸リボフラビンナトリウム 10mg 塩酸ピリドキシン 20mg 無水カフェイン 200mg アミノエチルスルホン酸 2000mg ヨクイニン 2400mg ステビア抽出物 30mg 砂糖 26000mg 安息香酸ナトリウム 60mg リンゴ酸ナトリウム 100mg リンゴ酸 600mg クエン酸 適量 ミックスフルーツフレーバー 微量 精製水 全量 200ml (製造方法)実施例12と同様の方法で製造した(pH
=4.0)。Example 13 Calcium gluconate 800 mg Ammonium iron citrate 80 mg Magnesium L-aspartate 400 mg Riboflavin sodium phosphate 10 mg Pyridoxine hydrochloride 20 mg Anhydrous caffeine 200 mg Aminoethyl sulfonic acid 2000 mg Yokuinin 2400 mg Stevia extract 30 mg Sugar 26000 mg Sodium benzoate 60 mg Sodium malate 100 mg Malic acid 600 mg Citric acid Suitable amount Mixed fruit flavor Trace amount Purified water Total amount 200 ml (Production method) Production was carried out in the same manner as in Example 12 (pH
= 4.0).
【0028】実施例14 グルコン酸カルシウム 5000mg クエン酸鉄アンモニウム 120mg L−アスパラギン酸マグネシウム 2400mg 塩酸フルスルチアミン 20mg リン酸リボフラビンナトリウム 10mg 塩酸ピリドキシン 20mg 無水カフェイン 200mg アミノエチルスルホン酸 2000mg ヨクイニン 2400mg 還元麦芽糖水飴 10000mg 異性化糖 30000mg 安息香酸ナトリウム 60mg フマル酸一ナトリウム 100mg リンゴ酸 400mg 酒石酸 適量 レモンリキュールフレーバー 微量 精製水 全量 200ml (製造方法)実施例12と同様の方法で製造した(pH
=4.0)。Example 14 Calcium gluconate 5000 mg Ammonium ferric citrate 120 mg Magnesium L-aspartate 2400 mg Fursultiamine hydrochloride 20 mg Riboflavin sodium phosphate 10 mg Pyridoxine hydrochloride 20 mg Anhydrous caffeine 200 mg Aminoethylsulfonic acid 2000 mg Yokuinin 2400 mg Reduced maltose starch syrup 10000 mg Saccharified sugar 30000 mg Sodium benzoate 60 mg Monosodium fumarate 100 mg Malic acid 400 mg Tartaric acid Appropriate amount Lemon liqueur flavor Small amount of purified water Total amount 200 ml (Production method) Produced by the same method as in Example 12 (pH).
= 4.0).
【0029】実施例15 グルコン酸カルシウム 1000mg クエン酸鉄アンモニウム 100mg L−アスパラギン酸マグネシウム 500mg ジセチアミン 20mg リン酸リボフラビンナトリウム 10mg 塩酸ピリドキシン 20mg 無水カフェイン 200mg アミノエチルスルホン酸 2000mg ヨクイニン 2400mg ジオウ 600mg ニンジン 2000mg ローヤルゼリー 500mg センキュウ 1000mg ステビア抽出物 30mg 砂糖 26000mg 安息香酸ナトリウム 60mg リンゴ酸ナトリウム 100mg クエン酸 600mg リンゴ酸 適量 ミックスフレーバー 微量 精製水 全量 200ml (製造方法)実施例12と同様の方法で製造した(pH
=3.5)。Example 15 Calcium Gluconate 1000 mg Ammonium Iron Citrate 100 mg Magnesium L-Aspartate 500 mg Dicethiamine 20 mg Riboflavin Sodium Phosphate 10 mg Pyridoxine Hydrochloride 20 mg Anhydrous Caffeine 200 mg Aminoethyl Sulfonic Acid 2000 mg Yokuinin 2400 mg Dioce 600 mg Carrot 2000 mg Royal Jelly Stevia extract 30 mg Sugar 26000 mg Sodium benzoate 60 mg Sodium malate 100 mg Citric acid 600 mg Malic acid Appropriate amount Mix flavor Small amount of purified water Total amount 200 ml (Production method) Produced by the same method as in Example 12 (pH
= 3.5).
【0030】試験例 前記実施例及び比較例で調製した、18種類のクエン酸
鉄アンモニウムを配合した水溶液について官能試験を行
った。評価方法は次の通りである。専門パネルは、22
才から39才までの男性8人、女性8人の計16人を用
いた。風味の評価は、サンプル10mlを服用し鉄味に
ついて絶対評価した。1つのサンプルを評価した後は、
お湯を用い口腔内を洗浄し、30分経過後に次のサンプ
ルを評価した。結果を表1に示した。Test Example A sensory test was performed on the aqueous solutions prepared by mixing the 18 types of ammonium iron citrate prepared in the above Examples and Comparative Examples. The evaluation method is as follows. 22 specialized panels
A total of 16 men, eight men and eight women aged 39 to 39 were used. For the evaluation of flavor, 10 ml of the sample was taken and the iron taste was evaluated absolutely. After evaluating one sample,
The inside of the oral cavity was washed with hot water and the following samples were evaluated after 30 minutes. The results are shown in Table 1.
【0031】[0031]
【表1】 [Table 1]
フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 31:70) (72)発明者 水谷 卓 東京都豊島区高田3丁目24番1号 大正製 薬株式会社内Continuation of the front page (51) Int.Cl. 6 Identification number Reference number within the agency FI Technical indication location A61K 31:70) (72) Inventor Taku Mizutani 3-24-1 Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd. Within
Claims (6)
の有機酸を0.05〜2.0重量%でかつ有機鉄化合物
中の鉄成分1重量部に対して3〜300重量部になるよ
う配合し、pHが2.5〜5.0である鉄化合物配合内
服液剤。1. An organic iron compound and one or more organic acids in an amount of 0.05 to 2.0% by weight and 3 to 300 parts by weight per 1 part by weight of the iron component in the organic iron compound. An oral solution containing an iron compound, which is formulated to have a pH of 2.5 to 5.0.
%であり、かつ有機鉄化合物中の鉄成分1重量部あたり
1〜40重量部のカルシウム化合物を含む請求項1記載
の鉄化合物配合内服液剤。2. The iron compound-containing oral administration according to claim 1, wherein the calcium component is 0.001 to 1.0% by weight, and 1 to 40 parts by weight of the calcium compound is contained per 1 part by weight of the iron component in the organic iron compound. Liquid agent.
0.01〜2.0重量%でかつ有機鉄化合物中の鉄成分
1重量部に対して2〜60重量部である請求項2記載の
鉄化合物配合内服液剤。3. A compounding amount of one or more kinds of organic acids is 0.01 to 2.0% by weight and 2 to 60 parts by weight with respect to 1 part by weight of the iron component in the organic iron compound. Item 3. An iron compound-containing oral liquid preparation according to item 2.
である請求項3記載の鉄化合物配合内服液剤。4. The iron compound-containing oral liquid preparation according to claim 3, wherein the organic iron compound is ammonium iron citrate.
ムである請求項2ないし4記載の鉄化合物配合内服液
剤。5. The iron compound-containing oral liquid preparation according to claim 2, wherein the calcium compound is calcium gluconate.
酸、リンゴ酸、フマル酸、酒石酸、乳酸及びコハク酸か
らなる群より選ばれる1種または2種以上の化合物」で
ある請求項1ないし5記載の鉄化合物配合内服液剤。6. The one or more kinds of organic acids are “one or more kinds of compounds selected from the group consisting of citric acid, malic acid, fumaric acid, tartaric acid, lactic acid and succinic acid”. The oral liquid preparation containing the iron compound according to any one of 1 to 5.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP00619596A JP4029431B2 (en) | 1996-01-18 | 1996-01-18 | Iron compound combination oral solution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP00619596A JP4029431B2 (en) | 1996-01-18 | 1996-01-18 | Iron compound combination oral solution |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09194356A true JPH09194356A (en) | 1997-07-29 |
JP4029431B2 JP4029431B2 (en) | 2008-01-09 |
Family
ID=11631772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP00619596A Expired - Lifetime JP4029431B2 (en) | 1996-01-18 | 1996-01-18 | Iron compound combination oral solution |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4029431B2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000169385A (en) * | 1998-12-10 | 2000-06-20 | Taisho Pharmaceut Co Ltd | Internal liquid pharmaceutical preparation |
JP2002080347A (en) * | 2000-09-04 | 2002-03-19 | Taisho Pharmaceut Co Ltd | Oral liquid medicine formulated with iron compound |
JP2005298484A (en) | 2004-03-15 | 2005-10-27 | Taisho Pharmaceut Co Ltd | Zinc compound-formulated composition |
US7090878B2 (en) | 2001-05-31 | 2006-08-15 | The Procter & Gamble Company | Mineral fortified water |
US7279187B2 (en) | 2003-02-14 | 2007-10-09 | The Procter & Gamble Company | Mineral fortification systems |
JP2015092834A (en) * | 2013-11-08 | 2015-05-18 | ハウス食品株式会社 | Oral composition with carbonic feel, and carbonic feel-imparting agent |
JP2017508799A (en) * | 2014-03-12 | 2017-03-30 | シールド ティーエックス (ユーケー) リミテッド | Composition |
EP3735238A4 (en) * | 2018-01-02 | 2021-11-03 | Kashiv Biosciences, LLC | A stable oral pharmaceutical composition of ferric citrate |
-
1996
- 1996-01-18 JP JP00619596A patent/JP4029431B2/en not_active Expired - Lifetime
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000169385A (en) * | 1998-12-10 | 2000-06-20 | Taisho Pharmaceut Co Ltd | Internal liquid pharmaceutical preparation |
JP2002080347A (en) * | 2000-09-04 | 2002-03-19 | Taisho Pharmaceut Co Ltd | Oral liquid medicine formulated with iron compound |
US7090878B2 (en) | 2001-05-31 | 2006-08-15 | The Procter & Gamble Company | Mineral fortified water |
US7279187B2 (en) | 2003-02-14 | 2007-10-09 | The Procter & Gamble Company | Mineral fortification systems |
JP2005298484A (en) | 2004-03-15 | 2005-10-27 | Taisho Pharmaceut Co Ltd | Zinc compound-formulated composition |
JP2015092834A (en) * | 2013-11-08 | 2015-05-18 | ハウス食品株式会社 | Oral composition with carbonic feel, and carbonic feel-imparting agent |
JP2017508799A (en) * | 2014-03-12 | 2017-03-30 | シールド ティーエックス (ユーケー) リミテッド | Composition |
EP3735238A4 (en) * | 2018-01-02 | 2021-11-03 | Kashiv Biosciences, LLC | A stable oral pharmaceutical composition of ferric citrate |
Also Published As
Publication number | Publication date |
---|---|
JP4029431B2 (en) | 2008-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4051717B2 (en) | Biotin-containing oral solution | |
JP2003274896A (en) | Bitter taste reduction agent for amino acids tasting bitter and use thereof | |
RU2012138581A (en) | ORGANOLEPTIC ACCEPTABLE ORAL DOSAGE FORM OF IBUPROFEN AND METHODS FOR ITS PREPARATION AND APPLICATION | |
KR100472590B1 (en) | Oral Intake Solution | |
JPH09194356A (en) | Internal liquid preparation compounded with iron compound | |
JP4929628B2 (en) | Zinc-containing oral solution | |
GB2564444A (en) | Liquid pharmaceutical composition of flecainide | |
JP4622006B2 (en) | Iron compound-containing oral solution composition | |
JP4403595B2 (en) | Iron compound-containing oral solution composition | |
JP4990515B2 (en) | Isosorbide preparation with improved taste quality | |
JP2006306848A (en) | Copper compound-incorporated composition for liquid preparation for internal use | |
JP4206506B2 (en) | Solution containing vitamin B1 | |
JPH11139992A (en) | Liquid composition for drinking | |
JP4789292B2 (en) | Oral solution with improved flavor | |
JP4013267B2 (en) | Oral solution | |
JP2000044469A (en) | Internal liquid medicine | |
KR100907201B1 (en) | Liquid medicine for internal use | |
EP1175906A1 (en) | Blood flow improvers and thrombosis preventives or remedies comprising glucosamine | |
JP4407006B2 (en) | Iron compound combination oral solution | |
JP2000239154A (en) | Internal medicine composition containing iron compound | |
CN110151688A (en) | A kind of ambroxol hydrochloride injection composition and preparation method thereof | |
KR102342514B1 (en) | A pharmaceutical composition in the form of an aqueous solution for oral administration comprising magnesium glycerophosphate | |
JP4228403B2 (en) | Solution containing vitamin B1 | |
JP2000239155A (en) | Internal medicine composition containing iron compound | |
JP4193218B2 (en) | Biotin dissolution method and biotin-containing internal solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070403 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070601 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070925 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071008 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101026 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101026 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101026 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111026 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111026 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121026 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121026 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131026 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |